Neuren Pharmaceuticals Limited
Overview
Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration using analogues and derivatives of naturally occurring neuroprotective peptides. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Through its subsidiary, Perseis Therapeutics, Neuren is also engaged in research and development of antibodies to breast and other cancers..JPG){kind=logo}
Main business focus/
Listing by sector:
- Neurology
- Drug Discovery & Development
- Clinical Trials
- Oncology
Competitive Advantages
Neuren's neurology programs utilise analogues or derivatives of naturally ccurring neuroprotective peptides with multiple modes of action across different populations of brain cells and with inherently strong safety profiles. Virtually all direct R&D expenditures are covered by non-dilutive grant funding from the US Army and granting agencies in Australia and New Zealand.
Technology/IP
NNZ-2566: lead analogue of IGF-1(1-3) n-terminal tripeptide; unique mechanism of action targets microglial activation and post-injury seizures; in Phase II for moderate to severe brain injury; oral form in development for mild TBI and other indications; composition of matter and method of use patents granted
Motiva: oral small molecule drug in Phase II for apathy and depression in post-stroke patients; positive clinical results from completed Phase IIb trial under US IND; positive safety and efficacy data from 6 Phase II and III trials in Japan in >1700 patients
NNZ-2591: lead analogue in diketopiperazine library; 100% orally available; positive data in animal models of Parkinson's disease, peripheral neuropathy and cogonitive impairment; composition of matter and method of use patents granted
Corporate Alliances/Partnerships
US Army Walter Reed Army Institute of Research/Medical Research and Materiel Command
Rett Syndrome Research Trust
Department of Neuropsychiatry/University of Western Australia
New Zealand Breast Cancer Research Trust
Partnering Opportunities
Neuren is committed to seeking partnerships with larger companies with the resources and experience to manage large-scale clinical trials and achieve product approval and commercialisation. Neuren is also seeking out-licensing or collaboration opportunities for its preclinical drug candidates, including: |
|
Contact Details
| Contact person | Mr Larry Glass |
|---|---|
| Job Title | CEO |
| Address | 3 Bethesda Metro Center |
| Suite 700 | |
| City/Suburb | Bethesda, Maryland USA |
| State | Select a State/Territory... |
| Operating State | Select an Operating State/Territory... |
| lglass@neurenpharma.com | |
| Phone | +1-301-758-2987 |
| Website | http://www.neurenpharma.com |
